PRA Health (PRAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Those holding PRA Health Sciences (NASDAQ:PRAH) shares must be pleased that the share price has rebounded 33% in the...
PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic. The educational program, which provides vital sign tracking, prevention techniques and mental health support for those who are asymptomatic.
PRA Health Sciences (PRAH) announced today a partnership between Symphony Health and Datavant that expands the breadth of data available for integration and allows life sciences companies to get the deepest and most holistic view of the patient journey in the commercial market. Symphony Health’s proprietary Synoma® de-identification engine enables integration of complementary data sets from across the health ecosystem using a unique token. By leveraging best-in-class de-identification and integration with Symphony Health’s proprietary Synoma engine, customers will be able to connect, expand and analyze all relevant data types – electronic health records, medical and pharmacy claims, diagnostic lab datasets, demographics, and information from patient wearables and sensors collected during clinical trials.
PRA Health's (PRAH) new module is likely to boost Data Solutions segment.
Net new business of $604.7 million; Net book-to-bill of 1.10 excluding reimbursement revenueNet new business of $955.9 million; Net book-to-bill of 1.32 including reimbursement.
PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.
PRA Health Sciences (PRAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.
As a response to the ongoing global COVID-19 pandemic, PRA Health Sciences announced today the expansion of its industry-leading Mobile Health Platform for remote clinical monitoring, adding several new capabilities that address sponsor needs for COVID-19 virtual study support. PRA’s Mobile Health Platform (MHP) engages with patients wherever they are. The new capabilities added to address COVID-19 are designed to support clinical trial sponsors and sites participating in clinical studies by allowing them to connect and coordinate with patients who are no longer able to travel to sites due to the current pandemic.
Ladies and gentlemen, thank you for standing by, and welcome to the PRA Health Sciences First Quarter 2020 Earnings Release Conference Call. Good morning, and thank you for joining us for the PRA Health Sciences First Quarter of 2020 Earnings Teleconference. Today, Colin Shannon, our Chief Executive Officer; and Mike Bonello, our Chief Financial Officer, will discuss our quarterly financial results.
RALEIGH, N.C., April 08, 2020 -- PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly.
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 0.96% and 3.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Unfortunately for some shareholders, the PRA Health Sciences (NASDAQ:PRAH) share price has dived 38% in the last...
Q1 2020 PRA Health Sciences Inc Earnings Call
A Triangle CRO's technology wing has launched a platform allowing for greater patient management for health systems and large employers, which it hopes will help stem the surge of COVID-19 hitting hospitals.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]